AC Immune S.A.

ACIU • Biotechnology

$2.86

▼ -0.07 (-2.39%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$282.21M

Crecimiento

-13.9%

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Nivel de deuda manejable · 0.1Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.86

Change-2.39%

Shares Out98.67M

Market Cap$282.21M

52W Range2.03 - 4.00

Beta1.57

P/E-4.72

P/S249.59

P/B8.86

P/FCF0.00

EV/Sales180.45

EV/EBITDA-13.70

Price$2.86

Change-2.39%

Shares Out98.67M

Market Cap$282.21M

52W Range2.03 - 4.00

Beta1.57

P/E-4.72

P/S249.59

P/B8.86

P/FCF0.00

EV/Sales180.45

EV/EBITDA-13.70

EV/FCF0.00

Earnings Yield-5.30%

FCF Yield0.00%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-19.27%

Profit Margin-19.72%

Debt/Eq0.10

Current Ratio1.02

Quick Ratio1.02

Revenue 5Y-13.87%

Target$7.00

Target Upside144.76%

Target Median$7.00

Target Range7.00 - 7.00

Volume117.99K

Avg Volume268.74K

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

57/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

38/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.1Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

ACIU

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

94/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-05

Bajo

$7.00

Promedio

$7.00

Mediana

$7.00

Alto

$7.00

Resumen de la compañía

IPO: 9/23/2016

Industria: Biotechnology

P/B i: 8.86

Deuda / Patrimonio i: 0.10

Margen operativo: -1927.32%

Margen neto: -1971.65%

ROE i: -

ROIC: -

Salud financiera

Puntaje11 / 20

Deuda / Patrimonio: 0.10

Ratio corriente: 1.02

Ratio rápido: 1.02

Estado: Moderate

Transacciones internas

Actividad reciente de ejecutivos e insiders

June Carl Howard

Transacción: 06/11/2026

COMPRA

Cambio

+38,889

Precio

$2.62

Presentación

06/15/2026

Tipo

COMPRA

June Carl Howard

Transacción: 06/11/2026

COMPRA

Cambio

+16,568

Precio

Not reported

Presentación

06/15/2026

Tipo

COMPRA

Buetler Monika

Transacción: 06/11/2026

COMPRA

Cambio

+41,667

Precio

$2.62

Presentación

06/15/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
June Carl Howard	COMPRA	+38,889	$2.62	06/11/2026	06/15/2026
June Carl Howard	COMPRA	+16,568	Not reported	06/11/2026	06/15/2026
Buetler Monika	COMPRA	+41,667	$2.62	06/11/2026	06/15/2026
Buetler Monika	COMPRA	+17,751	Not reported	06/11/2026	06/15/2026
Zuegel Martin	COMPRA	+33,136	Not reported	06/11/2026	06/15/2026
Zuegel Martin	COMPRA	+77,778	$2.62	06/11/2026	06/15/2026
AGUIAR-LUCANDER RENEE	COMPRA	+38,889	$2.62	06/11/2026	06/15/2026
AGUIAR-LUCANDER RENEE	COMPRA	+16,568	Not reported	06/11/2026	06/15/2026
Twyman Roy Ervin	COMPRA	+38,889	$2.62	06/11/2026	06/15/2026
Twyman Roy Ervin	COMPRA	+16,568	Not reported	06/11/2026	06/15/2026
Pfeifer Andrea	VENTA	-10,000	$2.79	05/15/2026	05/18/2026
Pfeifer Andrea	VENTA	-10,000	$3.14	04/15/2026	04/16/2026
Zuegel Martin	OTRO	+32,061	$1.84	03/18/2026	04/01/2026
Zuegel Martin	OTRO	0	Not reported	03/18/2026	04/01/2026
Donati Piergiorgio	OTRO	+89,552	$3.03	03/20/2026	03/20/2026
Donati Piergiorgio	OTRO	0	Not reported	03/20/2026	03/20/2026
June Carl Howard	OTRO	+43,299	$1.84	03/18/2026	03/18/2026
June Carl Howard	OTRO	0	Not reported	03/18/2026	03/18/2026
Pfeifer Andrea	OTRO	+644,444	$2.03	03/18/2026	03/18/2026
Pfeifer Andrea	OTRO	0	Not reported	03/18/2026	03/18/2026

Sobre la compañía

AC Immune S.A.

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

Fuente - Link

Competidores

ALDX AMRN ANNX ANRO CLLS CTNM DRTS LYEL MREO SLN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.

GlobeNewsWire

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.

Zacks Investment Research

AC Immune First Half 2026 Financial and Corporate Update

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer's disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda Cash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027 Lausanne, Switzerland, August 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today provided a corporate and financial update for the half-year ended June 30, 2026. Martin Zügel, MD, interim CEO of AC Immune and Chair of the Board of Directors, commented: “AC Immune is moving towards key clinical milestones in two of our wholly-owned programs, a growing focus for AC Immune.

GlobeNewsWire

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK. Across these AAIC presentations, we are showing how AC Immune's Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets.

GlobeNewsWire

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses Lausanne, Switzerland, June 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer's disease (AD) in the Phase 1b/2 ABATE trial following 12 months of treatment with ACI-24 anti-amyloid beta (Abeta) active immunotherapy. In the trial to date, ACI-24 has been generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema (ARIA-E).

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-30	-0.2	-0.19	0.01
2026-03-13	-0.19	-0.18	0.01
2025-11-04	-0.22	-0.2	0.02
2025-08-05	-0.2	-0.25	-0.05
2025-04-30	-0.22	-0.21	0.01
2025-03-13	-0.21	-0.18	0.03
2024-11-05	-0.2	0.05	0.25
2024-08-06	0.42	-0.25	-0.67
2024-05-13	-0.15	-0.21	-0.06
2024-03-14	-0.07	-0.06	0.01
2023-11-03	-0.02341	-0.2	-0.17659
2023-08-04	-0.22	-0.22	0